Ruslana G. Tytarenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ruslana G. Tytarenko has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Adam Rosenthal
Cancer Research and Biostatistics, Seattle, WA 98109, USA
1 shared publication - Aneta Mikulasova
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
1 shared publication - Anjan Thakurta
Celgene Corporation, Summit, NJ, USA
1 shared publication - Antje Hoering
Cancer Research and Biostatistics, Seattle, USA
1 shared publication - Brian A. Walker
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
1 shared publication - Christopher Paul Wardell
Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
1 shared publication
Latest Publications
- Open Access
Microhomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma
MYC is a widely acting transcription factor and its deregulation is a crucial event in many human cancers. MYC is important biologically and clinically in multiple myeloma, but the mechanisms underlying its dysregulation are poorly understood. We show that MYC rearrangements are present in 36.0% of newly diagnosed myeloma patients, as detected in the largest set of next generation sequencing data to date (n=1267). Rearrangements were complex and associated with increased expression of MYC and PVT1 , but not other genes at 8q24. The highest effect on gene expression was detected in cases where the MYC locus is juxtaposed next to super-enhancers associated with genes such as IGH , IGK , IGL , TXNDC5 / BMP6 , FAM46C and FOXO3 . We identified three hotspots of recombination at 8q24, one of which is enriched for IGH-MYC translocations. Breakpoint analysis indicates primary myeloma rearrangements involving the IGH locus occur through non-homologous end joining, whereas secondary MYC rearrangements occur through microhomology-mediated end joining. This mechanism is different to lymphomas, where non-homologous end joining generates MYC rearrangements. Rearrangements resulted in over-expression of key genes and ChIP-seq identified that HK2 , a member of the glucose metabolism pathway, is directly over-expressed through binding of MYC at its promoter.
Open AccessMicrohomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma
MYC is a widely acting transcription factor and its deregulation is a crucial event in many human cancers. MYC is important biologically and clinically in multiple myeloma, but the mechanisms underlying its dysregulation are poorly understood. We show that MYC rearrangements are present in 36.0% of newly diagnosed myeloma patients, as detected in the largest set of next generation sequencing data to date (n=1267). Rearrangements were complex and associated with increased expression of MYC and PVT1 , but not other genes at 8q24. The highest effect on gene expression was detected in cases where the MYC locus is juxtaposed next to super-enhancers associated with genes such as IGH , IGK , IGL , TXNDC5 / BMP6 , FAM46C and FOXO3 . We identified three hotspots of recombination at 8q24, one of which is enriched for IGH-MYC translocations. Breakpoint analysis indicates primary myeloma rearrangements involving the IGH locus occur through non-homologous end joining, whereas secondary MYC rearrangements occur through microhomology-mediated end joining. This mechanism is different to lymphomas, where non-homologous end joining generates MYC rearrangements. Rearrangements resulted in over-expression of key genes and ChIP-seq identified that HK2 , a member of the glucose metabolism pathway, is directly over-expressed through binding of MYC at its promoter.